个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Qian, C.[1] * ; Li, X.[1] ; Zhou, B.[1] ; Yuan, X.[1] ; Jiang, J.[1] ;
单位： [1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China
出处：
ISSN：

关键词： Small-cell lung cancer Tislelizumab Chemotherapy

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China
推荐引用方式(GB/T 7714)：
Qian C.,Li X.,Zhou B.,et al.Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S697-S698.
APA：
Qian, C.,Li, X.,Zhou, B.,Yuan, X.&Jiang, J..(2023).Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA：
Qian, C.,et al."Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S697-S698

相关文献

[1]Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC) [2]Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC) [3]Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [4]Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer [5]A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer [6]Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC) [7]Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer [8]Nutritional status changes in patients with advanced non-small cell lung cancer receiving first-line chemotherapy [9]Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) [10]Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer

资源点击量：432 今日访问量：0 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）